Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06586151 · ClinicalTrials.gov registry record · NA
Testing a Gender-inclusive HIV Prevention Program
A NA study of HIV Prevention, sponsored by Center for Innovative Public Health Research.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06586151: Recruiting NA study of HIV Prevention, sponsored by Center for Innovative Public Health Research.
NCT06586151 is a NA study of HIV Prevention that is actively recruiting participants, run by Center for Innovative Public Health Research. The registered enrollment target is 200 participants, below the 376-participant average among 32 other HIV Prevention trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06586151, a NA study of HIV Prevention, is actively recruiting participants, sponsored by Center for Innovative Public Health Research.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
If, over time, data suggest the intervention impacts HIV preventive behavior at the population level, it will be unique in that it can be quickly and cost effectively scaled up to impact thousands of trans girls and nonbinary youth assigned male at birth.
Primary Outcome
Self report of having been tested for either HIV or a sexually transmitted infection
Conditions Studied
Interventions
- BEHAVIORAL Transcendent Health
- BEHAVIORAL Text Messaging with Information
Study Locations (1)
California
- Center for Innovative Public Health Research - San Clemente
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-09-01 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What NCT06586151 shows while recruiting
NCT06586151 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 32 other HIV Prevention trials with a reported enrollment target (47% lower).
The record links to 1 condition, with HIV Prevention appearing as the primary indexed condition, and to 2 interventions - of which Transcendent Health is the first listed.
NCT06586151 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06586151 about?
NCT06586151 is a clinical study titled "Testing a Gender-inclusive HIV Prevention Program". If, over time, data suggest the intervention impacts HIV preventive behavior at the population level, it will be unique in that it can be quickly and cost effectively scaled up to impact thousands of trans girls and nonbinary youth assigned male at birth.
What is the current status of trial NCT06586151?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-09-01. Estimated completion is 2026-06-30.
What conditions does trial NCT06586151 study?
This clinical trial studies the following conditions: HIV Prevention.
What interventions are being tested in trial NCT06586151?
The interventions under investigation include: Transcendent Health (BEHAVIORAL), Text Messaging with Information (BEHAVIORAL).
Who is sponsoring clinical trial NCT06586151?
This trial is sponsored by Center for Innovative Public Health Research, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06586151 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Prevention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06586151's enrollment target sits among peer trials
200 13th of 32 higher than 20 of 32 other HIV Prevention trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Prevention trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Using PrEP, Doing It for Ourselves
RECRUITING · NA
-
Client-Centered Care Coordination for Black Men Who Have Sex With Men
RECRUITING · NA
-
Behavioral Economic Intervention to Improve HIV Behaviors in Sexual Minority Individuals
RECRUITING · NA
-
Intervention to Enhance PrEP Persistence
RECRUITING · NA
-
WePrEP: Developing a PrEP Shared Decision-making Tool for Transgender Women
RECRUITING · NA
-
Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI